Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pitolisant in Children and Adolescents with Autism Spectrum Disorders
2023-503678-18-00Phase 2Completed
- Sponsor
- Bioprojet
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing Pitolisant with Placebo (2 arms). Primary endpoint: Change from baseline of the SRS-2 total score to the end of treatment period. Started Aug 2023; status: completed.
02
Drugs
pitolisant
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on 2023-503678-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503678-18-00.